Can the acute-phase reactant proteins be used as cancer biomarkers?

Abstract

The association between the acute-phase reactant proteins (APRPs) and cancer has long been established. There have been numerous reports correlating altered levels of various APRPs with different types of cancers. However, researchers are often quick to dismiss the use of these APRPs as potential biomarkers for the diagnosis and monitoring of cancer because alterations in APRP concentrations are observed in a wide range of diseases. Recent progress in proteomics studies which profiled the serum proteins of cancer patients and those of normal individuals indicated that the altered APRP expressions were different for distinct types, subtypes, and even stages of cancer. Interestingly, these data are in agreement with those observed earlier using immunochemical and biochemical assays. In view of this compelling association of different patterns of APRPs with various types of cancers and in an apparent shift of paradigm, we present in this review some indications that APRP fingerprinting may be used as complementary cancer biomarkers.

• Authors: Wei Wei Pang, Puteri Shafinaz Abdul-Rahman, Wan Izlina Wan-Ibrahim, Onn Haji Hashim
• Journal: The International journal of biological markers (Int J Biol Markers) 2010 Jan-Mar Vol. 25 Issue 1 Pg. 1-11 ISSN: 0393-6155 [Print] United States
• PMID: 20155712 (Publication Type: Journal Article, Review)

Chemical References

• Acute-Phase Proteins
• Biomarkers, Tumor
• Cytokines

Topics

• Acute-Phase Proteins (analysis, immunology, physiology)
• Biomarkers, Tumor (blood)
• Cytokines (physiology)
• Humans
• Inflammation (blood, complications, immunology)
• Neoplasms (blood, diagnosis, etiology, immunology)
• Peptide Mapping
• Proteomics